Biomed Central Ltd

SHERPA: Unknown

People

  1. D'Angelo
    D'Angelo
  2. Kelly
    Kelly
  3. Tap
    Tap
  4. Chi
    Chi
  5. Gounder
    Gounder
  6. Antonescu
    Antonescu
  7. Avutu
    Avutu
  8. Bradic
    Bradic
  9. Chan
    Chan
  10. Dickson
    Dickson

Groups

  1. Department of Medicine (35)
  2. Sarcoma Service (35)
  3. Solid Tumor Oncology Division (35)
  4. Hematologic Malignancies, Division of (26)
  5. GSK Faculty (7)
  6. Tow Center for Developmental Oncology (TCDO) (7)
  7. Human Oncology and Pathogenesis Program (6)
  8. Hematology-Oncology Fellows (4)
  9. Weinberg Fellows (4)
  10. Department of Pathology and Laboratory Medicine (3)
Search Within
  1. "Sarcoma Service"
Formats
  1. Journal Article (18)
  2. Meeting Abstract (14)
  3. Guidelines (1)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Department of Medicine (35)
  2. Sarcoma Service (35)
  3. Solid Tumor Oncology Division (35)
  4. Hematologic Malignancies, Division of (26)
  5. GSK Faculty (7)
  6. Tow Center for Developmental Oncology (TCDO) (7)

More Groups

People
  1. Sandra D'Angelo (26)
  2. Ciara Kelly (8)
  3. William Tap (8)
  4. Ping Chi (6)
  5. Mrinal Gounder (4)
  6. Allison Richards (3)

More People

Years
  1. 2025 (3)
  2. 2024 (3)
  3. 2022 (6)
  4. 2021 (4)
  5. 2020 (7)
  6. 2019 (5)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (28)
  2. Journal of Hematology & Oncology (3)
  3. BMC Cancer (2)
  4. Cardio-Oncology (1)
  5. Journal of Experimental & Clinical Cancer Research (1)

Results (35)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy
    Journal Article

    Nacev, B. A.; Bradic, M.; Woo, H. J.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors
    Journal Article

    Milhem, M. M.; Wise-Draper, T. M.; Chandra, S.; Hanna, G. J.; Laux, D. E.; Medina, T. M.; Ansstas, G.; Daud, A.; Kelly, C. M.; O'Day, S. J.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
    Journal Article

    Movva, S.; Seier, K.; Bradic, M.; Charalambous, K.; Rosenbaum, E.; Kelly, C. M.; Cohen, S. M.; Hensley, M. L.; Avutu, V.; Banks, L. B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): Expansion cohorts and correlative analyses
    Journal Article

    Seligson, N. D.; Chen, J. L.; Goodrich, A. C.; Van Tine, B. A.; Campbell, J. D.; Richards, A. L.; Antonescu, C. R.; Liebner, D. A.; Milhem, M. M.; Streicher, H.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Expect the unexpected: Fulminant myocardial cytotoxic injury from Trabectedin
    Journal Article

    Tsay, A. J.; Satish, M.; Corley, E.; Ezema, A.; DeJesus, N.; Wisely, S.; McAleer, E.; Zhang, C.; Yuan, S.; Homan, E.; more...
    Cardio-Oncology (2024)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): From premalignant to metastatic disease
    Guidelines

    Luke, J. J.; Davar, D.; Andtbacka, R. H.; Bhardwaj, N.; Brody, J. D.; Chesney, J.; Coffin, R.; de Baere, T.; de Gruijl, T. D.; Fury, M.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
    Meeting Abstract

    D'Angelo, S.; Lebbé, C.; Mortier, L.; Brohl, A.; Fazio, N.; Grob, J. J.; Prinzi, N.; Hanna, G.; Hassel, J.; Kiecker, F.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression
    Meeting Abstract

    Klohe, E.; Suchindran, S.; Kapoor, G.; D'Souza, J.; Corigleano, E.; Araujo, D.; D'Angelo, S.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS)
    Meeting Abstract

    Kapoor, G.; Zajic, S.; Suchindran, S.; Kim, J.; Saxena, U.; Bhaskar, A.; Kaczynski, H.; Nathenson, M.; D'Souza, J.; Rich, B.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: Analysis from the phase 3 INVICTUS trial
    Journal Article

    Schöffski, P.; George, S.; Heinrich, M. C.; Zalcberg, J. R.; Bauer, S.; Gelderblom, H.; Serrano, C.; Jones, R. L.; Attia, S.; D’Amato, G.; more...
    BMC Cancer (2022)

    Fulltext@MSK | Save